Sepsis is a critical medical situation attributable to an awesome immune response to an an infection. It can result in organ failure and dying if not handled rapidly and successfully.
Research carried out by the IGC exhibits that these medicine can management irritation, making them potential therapies for sepsis.
Sepsis, the physique’s excessive response to an an infection, claims 11 million lives yearly. Simply eliminating the infectious agent just isn’t sufficient to outlive a extreme an infection, it is usually essential to mitigate the hurt attributable to each the an infection and the immune response to the organs. The Innate Immunity and Inflammation analysis group on the IGC focuses on this second side, which continues to be not part of the therapeutic intervention on sepsis.
A possible answer might come from a category of medicine generally utilized in most cancers therapy: anthracyclines. The analysis staff beforehand confirmed that these medicine can forestall organ failure in mice with sepsis with out impacting the an infection itself. This sparked a scientific trial in Germany to find out if using anthracyclines can enhance sepsis outcomes and decrease the danger of dying in sufferers. However, to completely make the most of these medicine, it’s obligatory to understand how they supply tolerance to an infection.
To discover this, researchers examined completely different anthracyclines within the immune system cells of mice. The outcomes had been shocking: these anticancer medicine restricted the degrees of pro-inflammatory mediators produced by the cells when administered in low doses. This impact was maintained when researchers handled mice with sepsis with these medicine.
The subsequent problem was to grasp how these medicine management irritation. “We discovered that anthracyclines control relevant inflammatory genes in the immune system cells”, explains Ana Neves-Costa, a researcher on the IGC and co-author of the research. By forming a posh with the cell’s DNA, these drugs avoid the binding of factors that drive the expression of these genes. As a result, cells produce less inflammatory molecules. “This new mechanism is particularly important because it lacks the side effects caused by administering high doses of these compounds in chemotherapy”, the researcher adds.
“With this work we found a possible new solution to treat diseases caused by exaggerated inflammation, such as sepsis and rheumatoid arthritis, more effectively”, explains Luís Moita, a doctor by training and principal investigator at the IGC leading the study. “Given that these drugs are already approved for use in the clinics, repurposing these for new treatments will be much easier than starting from scratch”, he adds. It is also likely that the regulation of gene expression and the limitation of inflammation described in this study, which were previously unrecognized, contribute to the effectiveness of anthracyclines in cancer treatment.
Reference: “DNA damage independent inhibition of NF-κB transcription by anthracyclines” by Angelo Ferreira Chora, Dora Pedroso, Eleni Kyriakou, Nadja Pejanovic, Henrique Colaço, Raffaella Gozzelino, André Barros, Katharina Willmann, Tiago Velho, Catarina F Moita, Isa Santos, Pedro Pereira, Silvia Carvalho, Filipa Batalha Martins, João A Ferreira, Sérgio Fernandes de Almeida, Vladimir Benes, Josef Anrather, Sebastian Weis, Miguel P Soares, Arie Geerlof, Jacques Neefjes, Michael Sattler, Ana C Messias, Ana Neves-Costa and Luis Ferreira Moita, 7 December 2022, eLife.
DOI: 10.7554/eLife.77443
This study was developed by the Instituto Gulbenkian de Ciência in collaboration with several national and international institutions, in particular the Instituto de Medicina Molecular (IMM) in Portugal, the Institute of Structural Biology and the European Molecular Biology Laboratory (EMBL) in Germany, and the Leiden University Medical Center in the Netherlands.
The study was funded by the European Commission Horizon 2020 and Fundação para a Ciência e Tecnologia (FCT).
Discussion about this post